A Phase 1 of CTX-8371 in Patients With Advanced Malignancies

Study Number

3833323

Phase

Age Group

Adult

Principal Investigator

Purpose

This is a Phase 1, open-label, first-in-human study of CTX-8371 administered as a monotherapy in patients with metastatic or locally advanced malignancies. The study will be conducted in 2 cohorts: Dose Escalation and Dose Expansion.

Check your eligibility for this trial

Check now

Full Title

A Phase 1, Open-Label, Multiple-Ascending Dose Study of the Safety and Tolerability of CTX-8371 in Patients with Advanced Malignancies

ClinicalTrials.Gov ID

NCT06150664

Get more information and eligibility criteria for this trial at ClinicalTrials.gov

To inquire about participating in these studies, call 1-800-ROSWELL (1-800-767-9355) or e-mail askroswell@roswellpark.org.